Ad Blocker Detected
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.
By now, the Omicron wave of the coronavirus has crested in much of the United States. But the size the wave, which broke records for national cases and hospitalizations, has given regulators and scientists an opportunity to better assess vaccine efficacy in children aged 6 months to 4 years old, Dr. Scott Gottlieb, a former commissioner of the Food and Drug Administration, said on Sunday.
Dr. Gottlieb, who sits on the board of the vaccine-maker Pfizer, said that he hopes key data expected on Friday will shed additional light on whether the federal government should grant emergency authorization for two doses of Pfizer-BioNTech’s vaccine for children in this age group.
“We now have an opportunity to look at a much richer data set,” Dr. Gottlieb, said on CBS’s “Face The Nation.” He did not specify what that data would reveal. Still, he emphasized that the toll Omicron took on children in particular gave Pfizer a stronger basis for comparison of those given vaccines and those not.
“Some got infected, hopefully some didn’t,” he said of the test group. “I think that’s what the data package is going to show, and I think it’s going to give a much clearer picture of” the vaccine’s efficacy against Omicron.
He said that the newer data will help illuminate results that had been less rich before the full Omicron wave had crested.
At the urging of the federal government, Pfizer and its partner BioNTech applied last week for authorization for two doses of its vaccine to children aged 4 and younger.
But results released in December did not show the hoped-for immune response in children aged 2 to 4. Children 6 months to 2 years old showed a comparable response to that of older teenagers and young adults.
The disappointing finding has led the companies to test a third shot in young children, but those results will not available for a few weeks. Still, in hopes of getting a jump start on the vaccination effort, the F.D.A. urged the companies to apply for authorization of two doses while everyone awaits data on the third dose.
The thinking is that if two doses are authorized and given, then children would be prepared for a third dose if and when research demonstrates that three shots prove fully effective.
That three doses will work is the working presumption of Pfizer and of some experts. Critics have argued that this strategy is short-circuiting the research process and that there is not yet clear evidence that a third dose will be make up for the inadequacies of two doses.
The Coronavirus Pandemic: Key Things to Know
Card 1 of 4
The state of the virus in the U.S. The coronavirus has now claimed more than 900,000 lives across the country, and the Covid death rates remain alarmingly high. The number of new infections, however, has fallen by more than half since mid-January, and hospitalizations are also declining.
Boosters. New data from the Centers for Disease Control and Prevention confirmed that booster doses are most beneficial to older adults. For younger Americans, vaccination decreased the risk of hospitalization and death so sharply that the additional shot did not seem to add much benefit.
Around the world. Several countries are easing their pandemic protocols, though public health leaders at the World Health Organization continued to urge caution about relaxing restrictions. In Austria, a sweeping Covid vaccine mandate is set to become law.
The full data on the trials have not been made public. But one person familiar with Pfizer’s research, who spoke on condition of anonymity, told The New York Times recently that children aged 6 months to 2 years old who got two doses got the infection at a 50 percent lower rate than a placebo group, while children 2 to 4 years old got it at a 57 percent lower rate.
Dr. Vivek Murthy, the surgeon general, said last week said no corners would be cut with Pfizer’s application for emergency authorization of the vaccine in young children. The application, he said, would “undergo the same independent, rigorous and transparent review process” that was used to clear the vaccine for adults. He also cited the role of the Omicron surge and its impact on children.
“Whether that changes the risk-benefit profile is what the F.D.A. will be assessing,” Dr. Murthy said. “But there has been developments since December on the data front.”